Cresci Vice-Chair of AHA Statement in Circulation

Associate Professor of Medicine and Associate Director of the Wash U Hypertrophic Cardiomyopathy Center, Dr. Sharon Cresci is Vice-Chair on a new statement published this week in the journal Circulation on behalf of the American Heart Association.

The statement, entitled “CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association”, addresses the variability of efficacy and safety of oral P2Y12 inhibitor therapy and associated risks.

From the abstract:

“The evidence to date supports CYP2C19 genetic testing before oral P2Y12 inhibitors are prescribed in patients with acute coronary syndromes or percutaneous coronary intervention. Clinical implementation of such genetic testing will depend on among multiple factors: rapid availability of results or adoption of the concept of performing preemptive genetic testing, provision of easy-to-understand results with therapeutic recommendations, and seamless integration in the electronic health record.”

View entire statement here